View the latest clinical trials, studies, data, and updates.
Their findings were published late last week in Proceedings of the National Academy of Sciences (PNAS)
The assay identifies a biologically low-risk subgroup within clinically high-risk patients, with outcomes similar to stage I disease, potentially sparing 30,000 women each year from unnecessary treatment intensification
This milestone marks the transition of years of dedicated research into clinical development, with the goal of delivering a transformative therapy for millions living with this debilitating lung condition
leural Dynamics’ innovative, fully implantable, patient motion powered shunt offers patients a low maintenance option for continuous relief from pleural effusions
Demonstrates that the VeraBIND Tau assay accurately measures active tau pathology—a key biomarker of Alzheimer’s disease (AD) and other tauopathies—in individuals with and without cognitive impairment.
Peer-reviewed findings demonstrate high disease control and quality-of-life preservation, supporting shift toward focal therapy in prostate treatment.